Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
- PMID: 23812094
- DOI: 10.1038/ijo.2013.120
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
Erratum in
- Int J Obes (Lond). 2013 Nov;37(11):1514
-
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study.Int J Obes (Lond). 2015 Jan;39(1):187. doi: 10.1038/ijo.2014.88. Epub 2014 Oct 14. Int J Obes (Lond). 2015. PMID: 25311036 No abstract available.
Abstract
Objective: Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced clinically meaningful weight loss in a phase 2 study in obese individuals without diabetes. The present randomized phase 3 trial assessed the efficacy of liraglutide in maintaining weight loss achieved with a low-calorie diet (LCD).
Methods: Obese/overweight participants (≥18 years, body mass index ≥30 kg m(-2) or ≥27 kg m(-2) with comorbidities) who lost ≥5% of initial weight during a LCD run-in were randomly assigned to liraglutide 3.0 mg per day or placebo (subcutaneous administration) for 56 weeks. Diet and exercise counseling were provided throughout the trial. Co-primary end points were percentage weight change from randomization, the proportion of participants that maintained the initial ≥5% weight loss, and the proportion that lost ≥5% of randomization weight (intention-to-treat analysis). ClinicalTrials.gov identifier: NCT00781937.
Results: Participants (n=422) lost a mean 6.0% (s.d. 0.9) of screening weight during run-in. From randomization to week 56, weight decreased an additional mean 6.2% (s.d. 7.3) with liraglutide and 0.2% (s.d. 7.0) with placebo (estimated difference -6.1% (95% class intervals -7.5 to -4.6), P<0.0001). More participants receiving liraglutide (81.4%) maintained the ≥5% run-in weight loss, compared with those receiving placebo (48.9%) (estimated odds ratio 4.8 (3.0; 7.7), P<0.0001), and 50.5% versus 21.8% of participants lost ≥5% of randomization weight (estimated odds ratio 3.9 (2.4; 6.1), P<0.0001). Liraglutide produced small but statistically significant improvements in several cardiometabolic risk factors compared with placebo. Gastrointestinal (GI) disorders were reported more frequently with liraglutide than placebo, but most events were transient, and mild or moderate in severity.
Conclusion: Liraglutide, with diet and exercise, maintained weight loss achieved by caloric restriction and induced further weight loss over 56 weeks. Improvements in some cardiovascular disease-risk factors were also observed. Liraglutide, prescribed as 3.0 mg per day, holds promise for improving the maintenance of lost weight.
Similar articles
-
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Int J Obes (Lond). 2012. PMID: 21844879 Free PMC article. Clinical Trial.
-
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.Int J Obes (Lond). 2014 May;38(5):689-97. doi: 10.1038/ijo.2013.149. Epub 2013 Aug 14. Int J Obes (Lond). 2014. PMID: 23942319 Free PMC article. Clinical Trial.
-
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Lancet. 2009. PMID: 19853906 Clinical Trial.
-
Liraglutide: A New Option for the Treatment of Obesity.Pharmacotherapy. 2015 Oct;35(10):926-34. doi: 10.1002/phar.1639. Pharmacotherapy. 2015. PMID: 26497479 Review.
-
Liraglutide in the treatment of obesity.Expert Opin Biol Ther. 2014 Aug;14(8):1215-24. doi: 10.1517/14712598.2014.925870. Epub 2014 Jun 6. Expert Opin Biol Ther. 2014. PMID: 24905058 Review.
Cited by
-
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?Curr Atheroscler Rep. 2024 Aug;26(8):341-351. doi: 10.1007/s11883-024-01214-6. Epub 2024 May 29. Curr Atheroscler Rep. 2024. PMID: 38809399 Review.
-
Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.Lancet Reg Health Eur. 2024 Feb 9;39:100853. doi: 10.1016/j.lanepe.2024.100853. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38803628 Free PMC article.
-
Female obesity: clinical and psychological assessment toward the best treatment.Front Endocrinol (Lausanne). 2024 May 3;15:1349794. doi: 10.3389/fendo.2024.1349794. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38765954 Free PMC article. Review.
-
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.J Obes. 2024 May 10;2024:8056440. doi: 10.1155/2024/8056440. eCollection 2024. J Obes. 2024. PMID: 38765635 Free PMC article. Review.
-
Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.Am J Cardiovasc Drugs. 2024 Jul;24(4):509-521. doi: 10.1007/s40256-024-00647-3. Epub 2024 May 11. Am J Cardiovasc Drugs. 2024. PMID: 38734847
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical